Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

198 EFALIZUMAB
EFALIZUMAB
Trade name: Raptiva (Genentech)
Indications: Psoriasis
Category: Immunomodulator; Monoclonal antibody
Half-life: 12–35 days
Clinically important, potentially hazardous interactions
with: immunosuppressives, live vaccines
Reactions
Skin
Abscess
Acne (4%)
Allergic reactions (sic)
Angioedema
Basal cell carcinoma
Cellulitis
Dermatitis
(2005): de Groot M+, Br J Dermatol 153(4), 843
Erythema multiforme
Erythroderma
(2004): Gaylor M-L G+, J Drugs Dermatol 3(1), 77 (following
withdrawal)
Inflammatory papules (sic)
(2007): Lowes MA+, BMC Dermatol 7, 2 (15 cases)
Lupus erythematosus
(2007): Heffernan MP+, J Drugs Dermatol 6(3), 310
(2006): Bentley DD+, JAmAcadDermatol54(5 suppl), S242
Lymphoma
(2006): Berthelot C+, Clin Lymphoma Myeloma 6(4), 329
Peripheral edema
(2006): Scheinfeld N, Expert Opin Drug Saf 5(2), 197
Psoriasis (0.7%)
(2006): Descamps V, Ann Dermatol Venereol 133(8-9 Pt 1), 666
(2006): Golda N+, J Drugs Dermatol 5(1), 63
(2005): Gregg LJ, Tulsa, OK (2 cases) (from Internet)
(observation)
(2005): Howard B, Santa Maria, CA (from Internet)
(observation)
(2004): Gaylor M-L G+, J Drugs Dermatol 3(1), 77 (recurrence)
(following withdrawal)
Skin cancer
(2006): Prescrire Int 15(81), 8
Squamous cell carcinoma
Urticaria
(2007): Heffernan MP+, J Drugs Dermatol 6(3), 310
Mucosal
Sialadenitis
(2006): Scheinfeld N, Expert Opin Drug Saf 5(2), 197
Other
Chills (13%)
(2006): Scheinfeld N, Expert Opin Drug 5(2), 197
(2004): Gaylor M-L G+, J Drugs Dermatol 3(1), 77 (13%)
Fever
(2006): Scheinfeld N, Expert Opin Drug Saf 5(2), 197
(2004): Gaylor M-L G+, J Drugs Dermatol 3(1), 77
Hepatotoxicity
(2006): Scheinfeld N, Expert Opin Drug Saf 5(2), 197
Hypersensitivity
(2006): Prescrire Int 15(81), 8
(2006): Descamps V, Ann Dermatol Venereol 133(8-9 Pt 1), 666
(2006): Scheinfeld N, Expert Opin Drug Saf 5(2), 197
Infections (29%)
(2007): Heffernan MP+, J Drugs Dermatol 6(3), 310
(staphylococcal abscess)
(2006): Prescrire Int 15(81), 8
(2004): Gaylor M-L G+, J Drugs Dermatol 3(1), 77 (29%)
Myalgia/Myositis/Myopathy/Myotoxicity (8%)
(2006): Scheinfeld N, Expert Opin Drug Saf 5(2), 197
Pain (10%)
(2004): Gaylor M-L G+, J Drugs Dermatol 3(1), 77 (10%)
Serum sickness
EFAVIRENZ
Trade name: Sustiva (Bristol-Myers Squibb)
Indications: HIV infection
Category: Antiretroviral; Non-nucleoside reverse transcriptase
inhibitor
Half-life: 52–76 hours
Clinically important, potentially hazardous interactions
with: alprazolam, benzodiazepines, chlordiazepoxide,
clonazepam, clorazepate, diazepam, dihydroergotamine, ergot,
flurazepam, lorazepam, methysergide, midazolam, oral
contraceptives, oxazepam, quazepam, temazepam, triazolam
Reactions
Skin
Eczema (